Recruiting
Phase 1
Phase 2

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Sponsor:

AstraZeneca

Code:

NCT05417594

Conditions

Advanced Solid Malignancies

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

AZD9574

Temozolomide

[11C]AZ1419 3391

Datopotamab Deruxtecan (Dato-DXd)

Trastuzumab Deruxtecan (T-DXd)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information